Comparison of the Efficacy and Safety of Left Atrial Appendage Closure and Direct Oral Anticoagulants for Atrial Fibrillation: A Meta-Analysis of Randomized Control Trials and Observational Studies

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jan 2

PMID 38164321

Authors

Calvin R Wei

Roy Lim

Sara Khan

Syed Ali Ahsan

Mohammad Al Omari

Nima D Sherpa

Zarwa Rashid

Areeba Khan

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to compare the efficacy and safety of left atrial appendage closure (LAAC) and direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF). This meta-analysis was conducted as per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines. Two investigators performed an online database search on PubMed, Web of Science, and Scopus databases from inception to October 31, 2023, without any language or time restrictions. Outcomes assessed in this meta-analysis included all-cause mortality, cardiovascular mortality, stroke, and major bleeding events. Eight studies were included in this meta-analysis, enrolling 7,629 participants with AF (4,287 in the DOAC group and 3,342 in the LAAC group). The pooled analysis showed that the risk of all-cause mortality was significantly higher in patients in the DOAC group compared to LAAC (relative risk (RR): 1.87, 95% confidence interval (CI): 1.50 to 2.34). The risk of cardiovascular mortality was 1.60 times higher in patients receiving DOACs compared to those receiving LAAC (RR: 1.60, 95% CI: 1.12 to 2.28). The risk of stroke was not significantly different between the two groups (RR: 1.15, 95% CI: 0.95 to 1.41). In conclusion, LAAC for AF patients proves to be safe and effective for stroke prevention, exhibiting a superior profile in terms of all-cause mortality, cardiovascular events, and major bleeding compared to oral anticoagulation (OAC). These findings prompt consideration of LAAC as a preferred treatment for cardiovascular event prevention in high-bleeding-risk patients.

References

Gallego P, Roldan V, Torregrosa J, Galvez J, Valdes M, Vicente V . Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012; 5(2):312-8. DOI: 10.1161/CIRCEP.111.967000. View

Ng A, Ng P, Ip A, Fung R, Chui S, Siu C . Clinical Outcomes of Left Atrial Appendage Occlusion Versus Switch of Direct Oral Antcoagulant in Atrial Fibrillation: A Territory-Wide Retrospective Analysis. J Am Heart Assoc. 2023; 12(20):e029421. PMC: 10757547. DOI: 10.1161/JAHA.123.029421. View

Bassand J, Virdone S, Badoz M, Verheugt F, Camm A, Cools F . Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021; 5(4):1081-1091. PMC: 7903226. DOI: 10.1182/bloodadvances.2020003560. View

Godino C, Melillo F, Bellini B, Mazzucca M, Pivato C, Rubino F . Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk. EuroIntervention. 2019; 15(17):1548-1554. DOI: 10.4244/EIJ-D-19-00507. View

Blackshear J, ODell J . Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996; 61(2):755-9. DOI: 10.1016/0003-4975(95)00887-X. View

Holmes Jr D, Doshi S, Kar S, Price M, Sanchez J, Sievert H . Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol. 2015; 65(24):2614-2623. DOI: 10.1016/j.jacc.2015.04.025. View

Kheiri B, Kumar K, Simpson T, Osman M, Dalouk K, Beitinjaneh B . Meta-analysis of Left Atrial Appendage Closure Versus Anticoagulation in Patients With Atrial Fibrillation. Am J Cardiol. 2020; 132:181-182. DOI: 10.1016/j.amjcard.2020.07.022. View

Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R . Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005; 36(6):1115-9. DOI: 10.1161/01.STR.0000166053.83476.4a. View

Holmes Jr D, Kar S, Price M, Whisenant B, Sievert H, Doshi S . Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64(1):1-12. DOI: 10.1016/j.jacc.2014.04.029. View

10.

Lippi G, Sanchis-Gomar F, Cervellin G . Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2020; 16(2):217-221. DOI: 10.1177/1747493019897870. View

11.

Turagam M, Osmancik P, Neuzil P, Dukkipati S, Reddy V . Left Atrial Appendage Closure Versus Oral Anticoagulants in Atrial Fibrillation: A Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2020; 76(23):2795-2797. DOI: 10.1016/j.jacc.2020.08.089. View

12.

Ding W, Rivera-Caravaca J, Fazio-Eynullayeva E, Underhill P, Gupta D, Marin F . Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Clin Res Cardiol. 2022; 111(9):1040-1047. PMC: 9424138. DOI: 10.1007/s00392-021-01983-z. View

13.

Nielsen-Kudsk J, Korsholm K, Damgaard D, Valentin J, Diener H, Camm A . Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation. JACC Cardiovasc Interv. 2021; 14(1):69-78. DOI: 10.1016/j.jcin.2020.09.051. View

14.

Ruff C, Giugliano R, Braunwald E, Hoffman E, Deenadayalu N, Ezekowitz M . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2013; 383(9921):955-62. DOI: 10.1016/S0140-6736(13)62343-0. View

15.

Glikson M, Wolff R, Hindricks G, Mandrola J, Camm A, Lip G . EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention. 2019; 15(13):1133-1180. DOI: 10.4244/EIJY19M08_01. View

16.

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

17.

Tiosano S, Banai A, Mulla W, Goldenberg I, Bayshtok G, Amit U . Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation-One-Year Survival. J Clin Med. 2023; 12(20). PMC: 10607551. DOI: 10.3390/jcm12206693. View

18.

Falasconi G, Gaspardone C, Godino C, Gaspardone A, Radinovic A, Pannone L . Left atrial appendage closure: a new strategy for cardioembolic events despite oral anticoagulation. Panminerva Med. 2021; 65(2):227-233. DOI: 10.23736/S0031-0808.21.04446-3. View

19.

Freeman J, Varosy P, Price M, Slotwiner D, Kusumoto F, Rammohan C . The NCDR Left Atrial Appendage Occlusion Registry. J Am Coll Cardiol. 2020; 75(13):1503-1518. PMC: 7205034. DOI: 10.1016/j.jacc.2019.12.040. View

20.

Korsholm K, Valentin J, Damgaard D, Diener H, Camm A, Landmesser U . Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: A propensity-score matched study. Int J Cardiol. 2022; 363:56-63. DOI: 10.1016/j.ijcard.2022.06.065. View